Clinical Design and Objectives

This multi-center, open-label Phase 1/2 trial evaluates the safety and efficacy of AB-3028 in patients with metastatic castration‑resistant prostate cancer (mCRPC). The study commenced on January 9 2026 and is currently enrolling. Phase 1 will assess dose safety, while Phase 2 will seek early efficacy signals.

Mechanism of Action and Differentiation

AB-3028 is a programming‑circuit T‑cell therapy that inserts a customized circuit into a patient’s T cells to recognize and eliminate cancer cells. Unlike conventional CAR‑T, its flexible circuit architecture enables adaptation to tumor heterogeneity, representing a differentiating advantage. This offers the potential for a novel therapeutic option in cancers such as prostate cancer, where immune‑evasion mechanisms are complex.

Current Treatment Landscape

Patients with mCRPC have limited options beyond standard hormonal therapy, chemotherapy, and radiation, and improving survival remains challenging. Approved immunotherapies are scarce, and most patients progress to advanced disease. Consequently, an innovative T‑cell‑based approach could address a significant unmet medical need.

Market and Investment Implications

The global mCRPC market is projected to reach approximately $600 million by 2025, with growing enthusiasm for immunotherapies. If AB-3028 demonstrates safety and efficacy, Arsenal Biosciences could substantially increase its pipeline valuation. Moreover, positive trial outcomes would likely strengthen the company’s position in partnership and licensing negotiations.